Javier Terriente - 15 September 2026 Zebrafish Heart Regeneration: A Screening Platform for Discovering Cardiac Repair Therapeutics
Myocardial infarction remains one of the leading causes of death and disability worldwide, and the reason is simple: the adult human heart cannot replace the muscle it loses. While we have spent decades searching for ways to reactivate cardiac muscle regeneration, zebrafish may hold the answer to accelerate our findings. They possess the ability to regenerate their heart after injury, without forming a permanent scar. Understanding how they do this is now driving a new generation of cardiac regeneration drug discovery.
Cardiac Regeneration After Myocardial Infarction: Why the Human Heart Fails to Repair Itself
Myocardial infarctions account for roughly half of all cardiovascular disease cases worldwide, with over 800,000 new cases estimated annually in the US alone. When a coronary artery becomes blocked, the resulting ischemia triggers cardiomyocyte necrosis and inflammation in the left ventricle, followed by fibrotic proliferation and adverse remodeling of the heart wall.
The core problem is that adult mammalian cardiomyocytes stop dividing shortly after birth. During development, cardiomyocytes actively proliferate, but they soon undergo a final round of division and exit the cell cycle, becoming mononucleated polyploid or binucleated diploid cells rather than retaining the ability to divide again. Without a population of cells able to replace what has been lost, the infarcted area is filled with scar tissue instead of functional myocardium, setting the stage for arrhythmias, recurrent infarction, and progressive heart failure. Despite improvements in early intervention that have reduced mortality, heart transplantation remains the only definitive treatment once the damage is done.
Radioisotope labeling studies have shown that a small fraction of adult human cardiomyocytes do turn over throughout life, but at a rate of less than 1%. This finding reopened the question of whether cardiomyocyte cell-cycle re-entry could be pharmacologically stimulated. To answer it, researchers turned to a handful of vertebrates that never lost this capacity, and zebrafish rapidly became the reference model.
Zebrafish Heart Regeneration: How Cardiomyocyte Dedifferentiation and Proliferation Restore Cardiac Muscle
In 2002, Poss and colleagues demonstrated that adult zebrafish hearts regenerate completely after up to 20% of the ventricle is surgically removed, with new myocardium replacing the clot within 30 to 60 days. Since then, cryoinjury and genetic ablation models have confirmed and extended this finding: zebrafish can recover from the loss of up to 60% of their cardiomyocytes, using distinct injury paradigms that all converge on the same regenerative outcome.
Genetic fate-mapping studies have established that new cardiomyocytes arise from pre-existing cardiomyocytes rather than from a resident stem cell population. Cells adjacent to the injury site dedifferentiate, undergoing sarcomere remodelling and re-expressing developmental genes such as gata4. Then, they re-enter the cell cycle, proliferating to replace the lost tissue.
The zebrafish heart regeneration process is supported by other cardiac cell types. Activated epicardial cells, coronary endothelial cells, and fibroblasts deliver paracrine and juxtacrine signals that create a pro-regenerative microenvironment around the wound.
Schematic summary of the regenerative processes after cryoinjury in the zebrafish heart. (A) Illustration of the anatomy and histology of an intact zebrafish heart. The ventricle comprises a trabecular myocardium (beige) that is surrounded by a thin layer of a compact myocardium (orange). (B) Illustration of the main cellular processes after cryoinjury during the regeneration time. Source: Bise T., et al. 2020.
A key structural advantage underlies this whole process. Unlike most adult mammalian cardiomyocytes, which become polyploid or binucleated, adult zebrafish cardiomyocytes remain mononucleated and diploid, a state that predisposes them to re-enter the cell cycle after injury. When zebrafish cardiomyocytes are experimentally pushed toward polyploidy, regeneration fails, underscoring how central this cellular state is to the whole regenerative program.
Why Drug Discovery Teams Study Zebrafish Heart Regeneration
What makes heart regeneration in zebrafish relevant to drug discovery is the degree of conservation of the underlying mechanisms across species. Many of the pathways first identified in zebrafish (Igf2, Vegfa, and Cxcl12/Cxcr4 signaling) have since been shown to modulate cardiomyocyte proliferation in neonatal mice. This cross-species conservation means that zebrafish findings can plausibly point toward druggable targets for stimulating cardiac repair and regeneration in adult humans.
Zebrafish also offer something mammalian regeneration models cannot: throughput. Because zebrafish embryos and larvae are small, optically transparent, and can be produced in the hundreds from a single breeding pair, they are compatible with automated, high-content screening formats that would be impossible in rodents. Transgenic reporter lines, such as cell-cycle indicators expressed specifically in cardiomyocytes, allow researchers to directly visualize and quantify proliferation in living animals.
For drug discovery teams, this translates into a practical opportunity: a whole-organism, in vivo model of cardiac repair and regeneration that can be used to screen compound libraries or validate genetic targets, while still capturing biology relevant to human cardiac repair.
Screening for Cardiac Regeneration Modulators: A Zebrafish-Based Platform for Cardiovascular Regenerative Medicine
This is the space where ZeCardio Therapeutics, our sister company, operates. ZeCardio has developed a dedicated zebrafish-based cardiovascular platform that combines robotic microfluidics and automated imaging with proprietary in-house software to quantify cardiac and vascular function in zebrafish larvae, including heart rate, arrhythmia, atrioventricular blockage, ejection fraction, blood flow, and vasodilation or vasoconstriction. At full capacity, the platform can screen up to 90 molecules per week or evaluate three genetic conditions in parallel, generating quantitative, decision-ready functional data.
Tomography of 3-day post-fertilization zebrafish larva labelling cardiomyocytes.
This level of quantitative, high-throughput phenotyping is the foundation ZeCardio's pipeline builds on across its three focus areas: cardioprotection against chemotherapy-induced cardiotoxicity, disease modeling for dilated and hypertrophic cardiomyopathy, and cardiac regeneration, where the goal is to apply this same functional phenotyping capacity to identify and validate compounds and targets capable of restoring function in the injured heart, building on the regenerative mechanisms described above.
As part of its efforts in cardiac regeneration, ZeCardio Tx is currently developing a novel small molecule with the potential to promote endogenous cardiac regeneration. The therapeutic target was originally discovered using zebrafish, and the molecule has already demonstrated promising efficacy in rodent models. Results from ongoing studies in pigs, a large-animal model with greater translational relevance to human cardiac physiology, are expected by the end of 2026.
In parallel, we developed ZebraReg, a zebrafish larva-based cardiac regeneration platform built around the controlled genetic ablation of cardiomyocytes. The platform enables rapid and cost-effective evaluation of novel regenerative targets and therapeutic candidates, providing an efficient in vivo system for early-stage discovery and prioritization before progression into more complex mammalian models.
For drug discovery teams working on cardiac repair, this kind of platform offers a way to generate functional cardiovascular data early, in a translatable organism with cardiac regeneration capacity.

Sources
Arqué F, Jung C, Muriel-Moreno B, López-Blanch L, Saman E, D'Amico D, Terriente J, Petrone P, Dyballa S. ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform. Brief Bioinform. 2026 Mar 1;27(2):bbag197. doi: 10.1093/bib/bbag197.
Apolínová K, Pérez FA, Dyballa S, Coppe B, Mercader Huber N, Terriente J, Di Donato V. ZebraReg—a novel platform for discovering regulators of cardiac regeneration using zebrafish. Front Cell Dev Biol. 2024 May 10;12:1384423. doi: 10.3389/fcell.2024.138442
Bise T, Sallin P, Pfefferli C, Jaźwińska A. Multiple cryoinjuries modulate the efficiency of zebrafish heart regeneration. Sci Rep. 2020 Jul 14;10(1):11551. doi: 10.1038/s41598-020-68200-1.
Brezitski KD, Goff AW, DeBenedittis P, Karra R. A Roadmap to Heart Regeneration Through Conserved Mechanisms in Zebrafish and Mammals. Curr Cardiol Rep. 2021 Mar 2;23(4):29. doi: 10.1007/s11886-021-01459-6.
Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002 Dec 13;298(5601):2188-90. doi: 10.1126/science.1077857.
Zuppo DA, Tsang M. Zebrafish heart regeneration: Factors that stimulate cardiomyocyte proliferation. Semin Cell Dev Biol. 2020 Apr;100:3-10. doi: 10.1016/j.semcdb.2019.09.005.
By Javier Terriente Javier is the co-founder of ZeClinics and ZeCardio Therapeutics, two biotech firms specializing in zebrafish-based preclinical drug discovery for cardiovascular, neural, and toxicology applications. He combines scientific leadership with business acumen, having successfully driven fundraising efforts and strategic partnerships.
Currently leading scientific efforts at ZeCardioTx (and formerly CSO at ZeClinics), Javier also serves on the Board of Directors of AseBio, where he advocates for industry collaboration. His academic background includes a PhD in Molecular Biology and a Marie Curie Fellowship. Recognized as an expert in zebrafish models, he has published extensively and has supervised five industrial PhD theses.